Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

BACKGROUND: Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We asse...

Bibliografske podrobnosti
Main Authors:	Lee, L, Campbell, R, Scheuermann-Freestone, M, Taylor, R, Gunaruwan, P, Williams, L, Ashrafian, H, Horowitz, J, Fraser, A, Clarke, K, Frenneaux, M
Format:	Journal article
Jezik:	English
Izdano:	2005

Podobne knjige/članki

Augmentation of glucose metabolism with perhexiline in non-ischaemic heart failure
od: Lee, L, et al.
Izdano: (2004)

Perhexiline.
od: Ashrafian, H, et al.
Izdano: (2007)

Effects of perhexiline on ketone body and triglyceride synthesis in patients with refractory angina or heart failure
od: Shivu, G, et al.
Izdano: (2008)

Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
od: Abozguia, K, et al.
Izdano: (2010)

Metabolic Modulation With Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
od: Abozguia, K, et al.
Izdano: (2009)

Metabolic modulation in heart failure: the coming of age.
od: Ashrafian, H, et al.
Izdano: (2007)

The pathophysiology of heart failure: a tale of two old paradigms revisited.
od: Ashrafian, H, et al.
Izdano: (2008)

Metabolic mechanisms in heart failure.
od: Ashrafian, H, et al.
Izdano: (2007)

METABOLIC ALTERATION IN HYPERTROPHIC CARDIOMYOPATHY (METAL-HCM STUDY): RANDOMISED DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF PERHEXILINE THERAPY IN PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY
od: Abozguia, K, et al.
Izdano: (2010)

Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy.
od: Gehmlich, K, et al.
Izdano: (2014)

Abnormal cardiac and skeletal muscle function and energetics correlate with insulin resistance in heart failure
od: Scheuermann-Freestone, M, et al.
Izdano: (2004)

Impaired energetics in heart failure - a new therapeutic target.
od: Ormerod, J, et al.
Izdano: (2008)

Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
od: Cher-Rin Chong, et al.
Izdano: (2022-09-01)

Prevalence of heart failure preserved ejection fraction in the community
od: Mahadevan, G, et al.
Izdano: (2007)

Modification of myocardial substrate use as a therapy for heart failure.
od: Abozguia, K, et al.
Izdano: (2006)

Proteomic characterisation of perhexiline treatment on THP-1 M1 macrophage differentiation
od: Bimala Dhakal, et al.
Izdano: (2023-03-01)

Hypoxic modulation of exogenous nitrite-induced vasodilation in humans.
od: Maher, A, et al.
Izdano: (2008)

Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo
od: Gabriela Reyes-Castellanos, et al.
Izdano: (2023-06-01)

Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects
od: Bimala Dhakal, et al.
Izdano: (2023-04-01)

Systemic nitrite selectively dilates veins and pulmonary vasculature, relieving diastolic ventricular interaction in advanced heart failure
od: Ormerod, J, et al.
Izdano: (2009)

Perhexiline treatment improves toxic effects of β‐adrenergic receptor stimulation in experimental peripartum cardiomyopathy
od: Tobias J. Pfeffer, et al.
Izdano: (2021-08-01)

Abnormal cardiac high-energy phosphate metabolism in a patient with type 2 diabetes mellitus.
od: Scheuermann-Freestone, M, et al.
Izdano: (2006)

Metabolic modulation in heart failure: high time for a definitive clinical trial.
od: Ashrafian, H, et al.
Izdano: (2011)

Effect of chronic peroxisome proliferator-activated receptor gamma (PPAR gamma) activation on cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes mellitus
od: Scheuermann-Freestone, M, et al.
Izdano: (2004)

Pacing in congestive heart failure
od: Frenneaux Michael P, et al.
Izdano: (2000-10-01)

The pathophysiology of heart failure
od: Ashrafian, H, et al.
Izdano: (2002)

DYNAMIC CHANGES IN LEFT VENTRICULAR FUNCTION ON EXERCISE IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE ROLE OF MYOCARDIAL ENERGY DEFICIENCY
od: Phan, T, et al.
Izdano: (2009)

Cardiac and skeletal muscle metabolism after chronic PPAR gamma activation in type 2 diabetes mellitus
od: Scheuermann-Freestone, M, et al.
Izdano: (2004)

Cardiac energetics in congestive heart failure.
od: Ashrafian, H
Izdano: (2002)

Response to letter regarding article, "The effect of selective heart rate slowing in heart failure with preserved ejection fraction"
od: Pal, N, et al.
Izdano: (2016)

Impaired active relaxation during dynamic exercise in patients with heart failure with a preserved ejection fraction (HfpEF)
od: Phan, T, et al.
Izdano: (2008)

Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.
od: Phan, T, et al.
Izdano: (2009)

Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure.
od: Nightingale, A, et al.
Izdano: (2007)

Genetic cardiomyopathies causing heart failure.
od: Cahill, T, et al.
Izdano: (2013)

New therapies for heart failure: is thalidomide the answer?
od: Davey, P, et al.
Izdano: (2000)

Despite improving endothelial function oral vitamin C increases phosphocreatine depletion during exercise in patients with chronic heart failure
od: Nightingale, A, et al.
Izdano: (2002)

Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive Systems.
od: Alessandra Guidi, et al.
Izdano: (2016-08-01)

Modulation of cardiac energetics as a target in ischemic heart disease
od: Ashrafian, H
Izdano: (2011)

Haemoglobin and flow-mediated vasodilation.
od: Madsen, P, et al.
Izdano: (2006)

PPARgamma activation improves cardiac energy metabolism in patients with type 2 diabetes Mellitus
od: Scheuermann-Freestone, M, et al.
Izdano: (2003)